To evaluate the feasibility and report the preliminary results for stereotactic radiosurgery (SRS) treatments of single or multiple brain metastases delivered with helical tomotherapy (HT) by means of the InterFix™ Radiosurgery kit. Between September 2010 and August 2012, thirty patients underwent SRS for treatment of 46 brain metastases with a median prescription dose of 20 Gy (range 15-21 Gy). Clinical response was assessed with 2-3 month intervals by magnetic resonance imaging (MRI). Dose distribution indexes were computed and compared with published data for SRS performed with dedicated machines. After a median follow-up of 14 months (range 4-31) the estimated overall survival (OS) rate was 70% at 6 months, 60% at 12 months and 44% at 18 months. Local control (LC) was 72% at 6 months, 65% at 12 months and 50% at 18 months. Acute toxicity as headache and epileptic crisis occurred in only two patients. The mean values of conformity, homogeneity and gradient score indexes were 1.36, 1.04 and 50 respectively. HT-SRS for single or multiple brain metastases appears a reliable technique with encouraging clinical outcomes and competitive dosimetrical results.
Introduction
Up to 30% of cancer patients presents brain metastases and the risk of developing varies according to primary tumour type: 50% lung cancer, 15-20% breast cancer, 10-15% unknown primary and 10-15% melanoma (1) . Whereas few patients treated for brain metastases die for extra cranial disease, the treatment of brain injuries is of great importance. It is well established that local treatment with surgery or radiosurgery allows excellent local control. While the role of adjuvant total brain irradiation is still under discussion (2) , radiosurgery arises as a viable alternative to surgery for treatment of single and particularly for multifocal brain metastases.
The techniques used for stereotactic radiosurgery (SRS) are currently different. Leksell Gamma Knife ® (Elekta AB, Stockholm, Sweden) is a dedicated machine for intracranial radiosurgical treatments. Other techniques for SRS include Volume 14 Number 6 December 2015 Technology in Cancer Research & Treatment 2014 April 16. Epub ahead of print multiple arc therapy with linear accelerators equipped with circular collimators or micro-multileaf collimator (MLC) and robotic systems like Cyberknife ® (Accuray, Sunnyvale, CA, USA). Advanced concepts in radiation therapy delivery techniques, such as volumetric or helical delivery of intensity modulated radiotherapy (IMRT) integrated with computed tomography (CT) imaging are now widely diffused. Helical tomotherapy (HT) (Accuray, Madison, WI, USA) has shown its potential as a precise stereotactic radiosurgery delivery system (3, 4) . The on-board megavoltage computed tomography (MVCT) system can achieve an accurate localization of the target because the high-contrast spatial resolution is similar to a diagnostic CT (5) and the longitudinal spatial resolution has been recently improved with the "J1" upgrade (reduction of jaw size) (6) using a 1 mm jaws aperture to produce MVCT projections. The image-guided treatments with HT coupled with a precise intracranial stereotactic positioning system (InterFix™ Radiosurgery kit) allow a submillimetre error delivery (7) (8) (9) .
This report assessed dose distribution indexes to compare HT with published data of SRS by dedicate techniques and details the clinical outcome of patients with single or multiple brain metastasis who underwent SRS with HT.
Materials and Methods

Patient Characteristics
Between September 2009 and June 2012, thirty patients, with a total of forty-six brain metastasis, underwent SRS with HT. All patients had diagnosis of carcinoma or melanoma with brain metastases that were newly diagnosed or relapsed after whole brain irradiation. Among all the 46 metastases treated, 14 (30%) were in frontal lobe, 2 (4%) in parietal lobe, 5 (11%) in temporal lobe, 2 (4%) in occipital lobe, 16 (35%) in the cerebellum, 4 (9%) in the motor area and 3 (7%) in the internal capsule. No patients presented metastases in the brain stem. Patients were classified according to the prognostic index of graded prognostic assessment (GPA) (10) and all patients had a life expectancy greater than 3 months. Patient details are shown in Table I . Two out of thirty (7%) patients had been previously irradiated for brain metastases: one patient underwent whole brain radiotherapy for adjuvant treatment after surgery and one patient had received 50 Gy in 20 fractions in the parietal lobe region. This protocol has been submitted and approved by our institutional Ethics Committee and all patients provided written informed consent before being assigned to treatment.
Patient Setup
To have an accurate identification of the targets, a day prior the treatment, a magnetic resonance imaging (MRI) was performed on a Philips Integra 1.5 T scanner. The MRI scan protocol used a T1 3D FFE (fast field echo) sequence with gadolinium contrast and full 3D reconstruction with 1 mm of slice thickness. For treatment setup the patients were immobilized with InterFix™ Radiosurgery kit (Integra Neurosciences, Burlington, USA). The kit is composed by a metal head ring with four skull pins secured, a table adapter and a computed tomography (CT) localizer frame with vertical and diagonal rods which results useful for patient alignment as well as for image registration (Figure 1 ). The carbon fibre table of the InterFix kit is designed to be firmly attached to the indexed HT treatment table. The day of the treatment, a CT scan with a 1.25 or 2.5 mm slice thickness from the vertex of the patient's to the second cervical vertebra was performed. The 5123512 CT images were fused with MRI using Oncentra v.3.3 (Elekta) for contouring of the targets and organs at risk (OARs). Image registration was performed using Oncentra's mutual information algorithm limited to the skull area and excluding the metallic ring and positioning rods of the InterFix system in order to prevent matching errors. Clinicians confirmed registration results by careful visual examination focusing primarily in the target area. Each target lesion was delineated as a separate clinical target volume (CTV). For the expansion of the CTVs to planning target volumes (PTV) a 3 mm isotropic margin was used. After registration and contouring the CT images were transferred to a HT Planning Station for treatment planning. HT system automatically under samples the CT images to 2563256 resolution (2 mm per pixel if using a 50 cm CT field-of-view) so particular care was adopted to verify again CTVs and PTVs boundaries of small targets transferred on the Planning Station.
Treatment Planning
Treatment planning of SRS targets was performed using HT Planning Station v.4. Dose was prescribed to the PTV's median dose (50%). Planning goals for PTVs were V 95 $ 98% and V 107 # 3% if not limited by normal tissue tolerances. Optimization of the treatment plans used all the relevant critical structures, including brain tissue, and a 1 cm ring structure to improve the dose fall-off outside of the PTVs. In the present study we did not use the special subvolume optimization techniques as suggested by Soisson et al. (11) , which the authors showed to improve conformity. Directional beam blocking for the fixation screws and eye structures was always used if necessary. In case of patients with multifocal disease, the opportunity to prepare two separate plans was evaluated, in order to reduce the beam on time (BOT). In general if all the metastases lied on the same or adjacent axial planes (we call these inplane lesions) a single plan was optimized to treat all the lesions ( Figure 2 ), while in the case of multiple foci with a cranio-caudal separation greater than 2 cm two separate plans were prepared. In this way a total of 39 plans were examined for the 30 patients included in this study. In 33 plans the 10 mm field width was used, while in the remaining 6 plans the 25 mm field width was used in order to reduce BOT due to the large craniocaudal extension of the targets. Typical values of helical pitch were 0.096 or 0.108 while modulation factor (MF) was generally set in the range 1.8-2.0 leading to a final MF of 1.8 on average (range 1.1-2.5).
Dose and Constraints
For SRS treatments the incidence of radionecrosis depends on the dose, volume and the region of treatment. Following the lines of RTOG criteria (12), we established a prescription dose as a function of the maximum diameter of the lesion. To treat metastases of diameter less than 2 cm a dose of 21 Gy was prescribed. For lesions between 2 and 2.5 cm, the prescribed dose was 18 Gy, while for metastases up to 3 cm the dose was 15 Gy. Patients with lesions larger than 3 cm were excluded from this study. A summary of dose constraints adopted for critical structures is listed in Table II (13-17 ).
Plan Evaluation
The treatment plans were analysed using the conformity, homogeneity and gradient score indexes. The indexes were in general computed per-lesion, the only exception being the case of multiple inplane lesions where the gradient score was computed taking into account all the lesions. In this paper the conformity index (CI) is defined as a modified inverse-Paddick index (18): where V TV is the volume comprised in the 95% isodose (treated volume), V PTV is the volume of the PTV and V PTV,T is the volume of the PTV covered by the 95% isodose. The inverse-Paddick index reduces to the conventional conformity index as proposed by ICRU 62 (19) in the case of full PTV coverage (i.e., V PTV,T 5 V PTV ).
Homogeneity index (HI) is defined as the ratio of the maximum dose in the PTV (D max ) and the prescription dose (D RX ):
The ability of the plan to spare normal tissue outside of the PTVs depends on the steepness of the dose gradient away from the targets. Wagner et al. (20) introduced the gradient score index (GSI) for stereotactic radiosurgery:
where R Eff,RX and R Eff,50%RX are the effective radii (expressed in cm) of the volume encompassed by the 95% isodose and the volume encompassed by the 50% isodose.
Treatment Setup
Before treatment delivery, a MVCT scan encompassing the whole longitudinal extent of the targets plus a margin of 1 cm in the cranio-caudal direction, using the fine (2 mm slice separation) scan set, was performed to verify and correct the patient setup. Two MVCTs were necessary when the treatment included two separate plans.
Outcomes Definition
Each patient was sent to clinical evaluation with MRI scans every 3 months. Acute toxicities were identified as events that onset within 90 days of the start of radiotherapy with accordance to CTCAE v 4.0 (21) . The local control (LC) was defined as a stabilization or reduction after treatment compared with the initial magnetic resonance. The standard Kaplan-Meier (K-M) method was used to estimate posttreatment overall survival (OS) and LC rate. Statistical analyses were performed using JMP v 10.0 (SAS Institute, Cary, NC). The comparison of two different K-M estimations to verify any difference between two sub-groups within the population study was performed with Wilcoxon, log-rank test and Tarone-Ware test, to reduce the statistical discrepancies between the weight used by each single test.
Results
Treatment Characteristics
Forty-six (76.6%) metastasis received 21 Gy, 8 lesions (17.0%) were irradiated with 18 Gy and 3 (6.4%) lesions received 15 Gy. For CTVs the volume range was 0.18-13.81 cc, the median volume was 1.9 cc and the average volume was 3.1 cc. The median and average PTV volume was 3.8 and 6.2 cc respectively with a range of 0.96-4.71 cc. The time required for patient setup and for the acquisition of the MVCT was about 10 minutes per plan. The BOT per plan was 20  6 minutes with a maximum of 49 minutes for a patient treated with two plans irradiating three metastatic lesions. The values of CI, HI and GSI are examined and compared to literature data in Table III ( [22] [23] [24] [25] [26] [27] [28] . The GSI scores have been analysed taking into account all the 46 lesions or partitioning the lesions in two groups: 32 "single" lesions (unifocal lesions and multifocal lesions for which at least one lesion was treated as a single with a separate plan) and 14 inplane lesions.
Toxicities and Outcomes
With a median follow-up of 14 months (range 4-31) the estimated LC was 72%, 65% and 50% at 6, 12 and 18 months respectively (Figure 3) . The 12 and 18 months OS was 60% and 44% (Figure 4) . Local control at 6 and 12 months was higher between patients treated with radiotherapy dose $20 Gy vs. ,20 Gy (82% and 31% vs. 43% and 14%) with a statistically significance found with all the above mentioned tests (p 5 0.006 with Wilcoxon) ( Figure 5 ). No differences in LC and OS were correlated with number of lesions and GPA score (.2 or #2). Acute toxicity was very mild. Twentyseven patients (93%) did not present any side effects even among the most frequent as erythema, vomiting, headache, nausea and hair loss. Only two patients presented disorders few days after radiosurgery: one patient presented grade 2 headache for important edema, while the other has developed an epileptic seizure. For both patients, after medical therapy, there was the disappearance of symptoms.
Discussion
The role and the effectiveness of radiosurgery have been investigated in many studies. Aoyama et al. (29) shows the values of local control at one year of 72.5%, and the author did not find difference in overall survival at 1 year between patients treated with radiosurgery alone and patients who received adjuvant total brain (28.4% vs. 38.5%). Other randomized studies reported values of local control after radiosurgery only around 67-74% (30, 31) . Our results achieved a 1 year LC and OS respectively of 65% and 60%. These results are promising, considering that 11/30 (37%) patients had multiple lesions before treatment and the reported toxicities were very low. The recently closed European Organization for the Research and Treatment of Cancer (EORTC) 22952-2600 trial addressed the role of WBRT after surgery or radiosurgery. This study enrolled 359 patients; local control after radiosurgery or surgery was 68% at two years. Addition of whole brain irradiation increased local control to 83%, but did not find statistically significant differences in overall survival (32, 33) . The whole brain radiation dose gives a biologically effectiveness contribution to enhance the efficacy of SRS in LC. As we report with our clinical outcomes, single doses lower than 20 Gy are not effective in the control of brain lesions, especially for larger ones (.2 cm). However the aim of our report is to evaluate the feasibility of performing SRS with HT in different brain metastatic clinical presentation and we could not add any suggestion to the efficacy of WBRT after SRS in brain metastases. HT has proven to be an accurate system for delivering a high dose to a small target also with the requirements of the radiosurgery (3). The first dosimetric data published from several years show that HT can be effectively used for radiosurgery (11, 22) .
The parameters for evaluation of a treatment plan in radiosurgery are widely described in literature. They include the conformity, the homogeneity and the gradient score indices used in this paper. Nakamura et al. (23) (25) reported the preliminary results of their experience with volumetric IMRT (Rapidarc). With mean volume of 5.2  6.0 cc the CI and HI were 1.32  0.20 and 1.08  0.03. We have not found significant difference between the CI and HI reported in this study and those published for other modalities of radiosurgery as shown in Table III , although the values of CI and HI depends on the dose normalization used in the treatment plan and the CI strongly depends on the PTV volume.
The GSI is a score scaled such that GSI $ 100 corresponds to an "optimal" 3 mm or less gradient for the 50% isodose. This ideal 3 mm gradient was obtained empirically from radiosurgery planning cases and corresponds to the gradient that is possible to achieve with linac radiosurgery when using multiple non-coplanar arcs and small (,20 mm) circular collimators. The GSI values reported by some authors, for other SRS modalities, ranges from 1.37  19.08 to 22.32  19.20 with IMRT to 43.28  13.78 with HT. Mayo et al. (25) reported in their analyses a GSI of 64.9  14.1 for Rapidarc. The average GSI values of our study are lower than the reference values reported by Wagner et al. (20) for spherical targets treated with arc therapy and small circular collimators. We found a mean value equal to 50  20 with a range 0.3-73. The large variability found in the present study of the values of GSI is related to the size of the metastasis and to the number of the irradiated lesions lying in the same plane. In fact if we consider only the "single" lesions the GSI score is 57  12 with a range 22-73, while the GSI for the inplane lesions group is 28  25 with a range 0.3-60.
In theory HT allows the irradiation of multiple lesions using a single radiosurgery plan. In effect, multiple metastases lying in the same or nearby planes (inplane lesions) can be treated concomitantly with great efficiency and there is no need to treat each target separately with a different isocenter as with conventional linac-based techniques. However the values of GSI for inplane lesions found in this work, evidence the lack of a rapid fall-off of the dose outside the PTV and a spreading of low doses that can add up each other if treating multiple lesions.
Conclusions
These mono-institutional preliminary results for HT-SRS of brain metastases appear to be very good with low toxicities. The dosimetric results obtained do not appear different from published data. Greater attention should be given in the case of lesions lying in the same or nearby planes, because this can widen the dose fall-off outside the targets. HT is a viable alternative to deliver radiosurgery for treatment of brain metastases.
